| 2025-02-18 | -79.9% | news | Investing.com | Bio-Path Holdings to be delisted from Nasdaq - Investing.com |
| 2024-06-03 | +53.7% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2023-08-03 | -46.6% | news | Seeking Alpha | Bio-Path prices 3.5M shares at $0.60 in public offering |
| 2023-08-03 | -46.6% | news | TradingView | Why Bio-Path Holdings (BPTH) Stock Is Down 45% - TradingView |
| 2024-04-18 | +33.5% | news | Seeking Alpha | Bio-Path announces $1.2M registered direct offering priced at-the-market |
| 2024-04-18 | +33.5% | news | Seeking Alpha | Bio-Path shares rally after clinical trial progress of BP1002 |
| 2024-04-18 | +33.5% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2024-04-19 | -30.5% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2024-04-19 | -30.5% | legal | SEC EDGAR | BPTH 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2024-10-08 | +27.8% | news | timothysykes.com | Unveiling Bio-Path’s Potential: BPTH’s Surprising Performance and Future Insights - timothysykes.com |
| 2023-08-07 | +22.1% | legal | SEC EDGAR | BPTH 8-K: 1.01, 3.03, 7.01 (SEC Filing) |
| 2024-02-21 | -20.3% | news | Seeking Alpha | Bio-Path announces 1-for-20 reverse stock split, effective Feb 22 |
| 2023-03-31 | -19.9% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2025-05-02 | +19.1% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2024-06-14 | +18.6% | legal | SEC EDGAR | BPTH 8-K: 8.01 (SEC Filing) |
| 2026-03-20 | +17.3% | legal | SEC EDGAR | BPTH 8-K: 5.03, 8.01 (SEC Filing) |
| 2021-08-13 | -16.5% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2026-02-24 | -15.9% | legal | SEC EDGAR | BPTH 8-K: 5.01, 5.03, 7.01and8.01 (SEC Filing) |
| 2024-11-15 | -15.8% | earnings | Seeking Alpha | Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript |
| 2024-11-15 | -15.8% | earnings | Seeking Alpha | Bio-Path GAAP EPS of -$0.70 |
| 2024-11-15 | -15.8% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2026-03-21 | +15.6% | news | Minichart | Bio-Path Holdings, Inc. Announces Domestication to Wyoming and Amendment Creating Series S Preferred Stock - Minichart |
| 2025-04-24 | -15.3% | news | Stock Titan | TCBPY Stock Price, News & Analysis - Stock Titan |
| 2024-03-08 | -15.0% | news | Seeking Alpha | Bio-Path files to sell 1.15M shares of common stock, warrants |
| 2024-03-08 | -15.0% | earnings | Seeking Alpha | Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript |
| 2024-03-08 | -15.0% | news | Seeking Alpha | Bio-Path reports FY results |
| 2024-03-08 | -15.0% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2024-03-14 | -13.8% | news | Seeking Alpha | Bio-Path gets Nasdaq's deficiency letter over minimum stockholders equity requirement |
| 2024-06-05 | -13.5% | legal | SEC EDGAR | BPTH 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2025-04-25 | -13.3% | news | Stock Titan | BPTH Stock Price, News & Analysis - Stock Titan |
| 2025-04-25 | -13.3% | news | Stock Titan | SYBE Stock Price, News & Analysis - Stock Titan |
| 2025-04-25 | -13.3% | news | Stock Titan | LADX Stock Price, News & Analysis - Stock Titan |
| 2025-04-25 | -13.3% | news | Stock Titan | TSOI Stock Price, News & Analysis | Therapeutic Solutions Intl - Stock Titan |
| 2024-06-12 | -11.3% | news | Seeking Alpha | Bio-Path files to sell 5.56M common stock, warrants |
| 2023-12-22 | +10.7% | news | Seeking Alpha | Bio-Path files to sell shares |
| 2024-05-15 | -10.3% | earnings | Seeking Alpha | Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript |
| 2024-05-15 | -10.3% | earnings | Seeking Alpha | Bio-Path GAAP EPS of -$4.88 misses by $0.34 |
| 2024-05-15 | -10.3% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2022-03-11 | -9.8% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2022-12-20 | -8.0% | legal | SEC EDGAR | BPTH 8-K: 5.02, 5.07 (SEC Filing) |
| 2024-07-11 | +7.3% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2021-12-13 | -6.8% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2022-02-18 | -6.4% | legal | SEC EDGAR | BPTH 8-K: 3.01 and 5.02 (SEC Filing) |
| 2024-10-17 | -6.4% | news | Seeking Alpha | Bio-Path files to sell 17.76M shares of common stock for holders |
| 2025-06-24 | -6.4% | legal | SEC EDGAR | BPTH 8-K: 5.02 and 8.01 (SEC Filing) |
| 2025-06-24 | -6.4% | executive | Investing.com | Bio-Path Holdings announces executive resignations and operational pause - Investing.com |
| 2024-03-26 | +6.2% | legal | SEC EDGAR | BPTH 8-K: 1.01, 3.02 (SEC Filing) |
| 2024-11-14 | -6.0% | earnings | Seeking Alpha | Bio-Path Q3 2024 Earnings Preview |
| 2021-05-14 | +5.9% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2021-08-19 | -5.8% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2023-11-15 | +5.5% | earnings | Seeking Alpha | Bio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call Transcript |
| 2023-11-15 | +5.5% | earnings | Seeking Alpha | Bio-Path GAAP EPS of -$0.32 beats by $0.02 |
| 2023-11-15 | +5.5% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2022-11-15 | -5.1% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2024-03-11 | -4.8% | legal | SEC EDGAR | BPTH 8-K: 8.01 (SEC Filing) |
| 2024-10-09 | -4.7% | news | Seeking Alpha | Bio-Path announces $4M private placement |
| 2024-12-13 | -4.7% | legal | SEC EDGAR | BPTH 8-K: 3.01, 5.02, 5.07 (SEC Filing) |
| 2025-02-19 | -4.6% | news | TradingView | BPTH Stock Price and Chart — OTC:BPTH - TradingView |
| 2021-10-27 | -4.2% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2021-12-17 | +4.1% | legal | SEC EDGAR | BPTH 8-K: 8.01 (SEC Filing) |
| 2022-08-16 | -4.1% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2022-04-06 | -4.1% | legal | SEC EDGAR | BPTH 8-K: 5.02, 7.01 (SEC Filing) |
| 2024-08-15 | -3.9% | earnings | Seeking Alpha | Bio-Path Holdings, Inc. (BPTH) Q2 2024 Earnings Call Transcript |
| 2024-08-15 | -3.9% | earnings | Seeking Alpha | Bio-Path GAAP EPS of -$1.16 |
| 2024-08-15 | -3.9% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2024-11-25 | -3.3% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2023-02-25 | +3.0% | news | GuruFocus | Heath Cleaver Net Worth (2026) - GuruFocus |
| 2024-02-17 | +2.9% | earnings | Yahoo Finance | When Can We Expect A Profit From Bio-Path Holdings, Inc. (NASDAQ:BPTH)? - Yahoo Finance |
| 2024-06-04 | -2.8% | news | Seeking Alpha | Bio-Path announces $4.0 million private placement |
| 2023-08-15 | -2.8% | earnings | Seeking Alpha | Bio-Path Holdings, Inc. (BPTH) Q2 2023 Earnings Call Transcript |
| 2023-08-15 | -2.8% | earnings | Seeking Alpha | Bio-Path GAAP EPS of -$0.53 misses by $0.01 |
| 2023-08-15 | -2.8% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2021-11-12 | -2.5% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2024-10-11 | -2.3% | legal | SEC EDGAR | BPTH 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2025-03-07 | +2.1% | legal | SEC EDGAR | BPTH 8-K: 1.01, 2.03, 3.02 (SEC Filing) |
| 2021-08-24 | +2.1% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2021-08-24 | +2.1% | legal | InvestorPlace | PTE Stock: The FDA News That Has Biotech Penny Stock PolarityTE Plunging Today - InvestorPlace |
| 2026-03-19 | +1.9% | news | Stock Titan | [8-K] BIO-PATH HOLDINGS, INC. Reports Material Event - Stock Titan |
| 2024-04-04 | -1.9% | legal | SEC EDGAR | BPTH 8-K: 1.01 and (SEC Filing) |
| 2024-03-27 | +1.7% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2023-05-12 | -1.5% | earnings | Seeking Alpha | Bio-Path Holdings, Inc. (BPTH) Q1 2023 Earnings Call Transcript |
| 2023-05-12 | -1.5% | earnings | Seeking Alpha | Bio-Path GAAP EPS of -$0.66 misses by $0.34 |
| 2023-05-12 | -1.5% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2024-04-15 | +1.4% | news | Seeking Alpha | Bio-Path gets newly issued patents in Mexico, Australia and Japan |
| 2024-04-15 | +1.4% | legal | SEC EDGAR | BPTH 8-K: 8.01 and (SEC Filing) |
| 2024-04-24 | -1.4% | news | Seeking Alpha | Bio-Path files to sell 484K shares of common stock for holders |
| 2025-03-28 | +1.4% | earnings | Seeking Alpha | Bio-Path GAAP EPS of -$4.12 |
| 2025-03-28 | +1.4% | legal | SEC EDGAR | BPTH 8-K: 1.01, 2.03, 3.02 (SEC Filing) |
| 2025-03-28 | +1.4% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |
| 2025-03-28 | +1.4% | news | Stock Titan | Bio-Path Slashes Annual Losses While Breakthrough Obesity Treatment Shows Promise - Stock Titan |
| 2026-03-25 | +1.2% | legal | Stock Titan | [1-A] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan |
| 2025-10-29 | +1.1% | legal | SEC EDGAR | BPTH 8-K: 5.02 (SEC Filing) |
| 2025-10-29 | +1.1% | news | TradingView | Bio-Path Holdings Announces Executive and Board Changes - TradingView |
| 2025-10-29 | +1.1% | executive | Stock Titan | BPTH names Vikram Grover to CEO/CFO roles; director changes - Stock Titan |
| 2025-11-14 | +0.9% | legal | SEC EDGAR | BPTH 8-K: 5.02 and 8.01 (SEC Filing) |
| 2025-11-14 | +0.9% | executive | Investing.com | Bio-Path Holdings announces board resignation and outlines turnaround plans - Investing.com |
| 2025-04-29 | -0.7% | legal | SEC EDGAR | BPTH 8-K: 1.01, 2.03, 3.02 (SEC Filing) |
| 2022-11-09 | -0.5% | legal | SEC EDGAR | BPTH 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2022-05-17 | -0.5% | legal | SEC EDGAR | BPTH 8-K: 2.02 and (SEC Filing) |